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Abstract
MIR233 is genetically or epigenetically silenced in a subset of acute myeloid leukemia
(AML).MIR223 is normally expressed throughout myeloid differentiation and highly ex-
pressed in hematopoietic stem cells (HSCs). However, the contribution ofMIR223 loss to
leukemic transformation and HSC function is largely unknown. Herein, we characterize
HSC function and myeloid differentiation inMir223 deficient mice. We show thatMir223
loss results in a modest expansion of myeloid progenitors, but is not sufficient to induce a
myeloproliferative disorder. Loss ofMir223 had no discernible effect on HSC quiescence,
long-term repopulating activity, or self-renewal capacity. These results suggest thatMIR223
loss is likely not an initiating event in AML but may cooperate with other AML associated on-
cogenes to induce leukemogenesis.
Introduction
MiRNAs regulate gene expression by targeting semi-complimentary messenger RNAs for post-
transcriptional silencing [1]. While somatic point mutations [2] and copy number alterations
[3] involving miRNA genes are uncommon in AML, we recently reported the hemizygous loss
of theMIR223 gene in a male patient with therapy-related AML [3]. Additionally,MIR223 has
been shown to be epigenetically silenced by AML-ETO [4] and down-regulated in several
blood cancers [5]. Although these studies collectively show thatMIR223 is commonly silenced
in leukemia, the contribution ofMIR223 loss to disease pathogenesis is unclear. A previous
study ofMir223 deficient mice suggested that miRNA-223 negatively regulates myeloid pro-
genitor proliferation [6]. However, miRNA-223 is highly expressed in HSCs [7,8] and its con-
tribution to HSC function has not been rigorously assessed. As HSCs and their properties are
fundamentally linked to leukemogenesis [9,10], we characterized the effect ofMir223 deletion
on HSC function to investigate how loss of this gene may contribute to normal and
malignant hematopoiesis.
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Methods
Mice
Sex- and age-matched wild-type,Mir223-/Y and femaleMir223-/- mice on a C57BL/6 back-
ground were obtained form The Jackson Laboratory and maintained under standard pathogen
free conditions. Mice were euthanized using carbon dioxide in a chamber using compressed
gas. All mouse experiments were approved by the Washington University Animal Care and
Use Committee (number 20122012).
Blood and bone barrow analysis
Peripheral blood and bone marrow were collected as described previously [11]. Complete
blood counts (CBCs) were obtained using a Hemavet 950 FS automated cell counter (Drew Sci-
entific). Bone marrow nucleated cells were quantified using a Cellometer Auto 2000 Cell Viab-
lity Counter (Nexcelom).
Flow Cytometry
Bone marrow and peripheral blood was processed for flow cytometry as previously described.
[12]. The following antibodies were used (all from eBiosciences unless otherwise indicated):
Gr-1 (RB6–8C5), B220 (RA3–6B2), CD3e (145–2C11), Ter119 (TER-119), Sca-1 (D7), c-kit
(2B8), CD34 (RAM34), FcγR (93), CD150 (Biolegend, TC15–12F12.2), CD41 (MWReg30),
and Flt3 (A2F10).
Cell cycle analysis was performed as previously described [13]. In brief, bone marrow cells
were stained for the indicated surface markers, fixed using the BD cytofix/cytoperm kit (BD),
blocked with 5% goat serum and stained with mouse anti-human Ki-67 (clone B56; BD Phar-
mingen). After washing, cells were resuspended in DAPI-containing FACS buffer. All cells
were analyzed on a Gallios flow cytometer (Beckman Coulter).
5-Fluorouracil Stress Response
Mice were given a single 150 mg/kg dose of 5-fluorouracil (5-FU) by intraperitoneal injection.
Peripheral blood was analyzed prior to treatment and 7, 9, 11, 14, 17, and 35 days after 5-
FU administration.
Bone Marrow Transplantation
Bone marrow transplantation was performed as previously described [13]. In brief, bone mar-
row from Ly5.2 wild-type orMir223 deficient mice was mixed at a 1:1 ratio with competitor
bone marrow from Ly5.1 wild-type mice. Cells were retro-orbitally injected at 4x106 cells/re-
cipient into congenic Ly5.1/Ly5.2 mice conditioned with 1,000 cGy from a 137Cesium source.
For serial transplantation studies, bone marrow from primary recipients was harvested at
least 6 weeks after transplantation, pooled, and transplanted into lethally irradiated Ly5.1
secondary recipients.
Statistical Analysis
Unpaired student's t-test was used for cell cycle analysis and all lineage, precursor, progenitor,
and stem cell population data; student's t-test with Welch's correction was used as necessary
when variances were significant between groups. 5-FU, competitive repopulation, and serial
transplantation studies were analyzed using 2-way ANOVA with Bonferroni post-test analysis.
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Results and Discussion
We utilized an established mouse model of constitutiveMir223 deletion to investigate the ef-
fects of miRNA-223 loss on hematopoiesis. These mice were originally characterized on a
mixed strain C57BL/6 x 129Sv/Jae background and developed a myeloproliferative syndrome
characterized by neutrophilia and pulmonary inflammation [6]. To eliminate the potential
confounding impact of strain differences on HSC function, we analyzed mice back-crossed
onto a C57BL/6 background. Peripheral blood and bone marrow counts were similar between
male and femaleMir223 deficient mice (Fig. 1 and data not shown); thus, data were pooled
with respect to gender. Peripheral blood counts were normal except for a modest reduction in
red blood cells inMir223 deficient mice (Fig. 2A). Surprisingly, neutrophil counts were similar
betweenMir223 deficient and control mice (Fig. 2B). Bone marrow cellularity was modestly in-
creased inMir223 deficient mice (Fig. 2C). Whereas the number of mature neutrophils in the
bone marrow was comparable to wild-type mice, a significant increase in Gr-1INTCD115- gran-
ulocytic precursors was observed inMir223 deficient mice (Figs. 2D and 2E). A bimodal
Fig 1. No gender specific alterations in hematopoiesis are present inMir223 deficient mice. (A and B)
Peripheral blood from 8–12 week old wild-type and (A) femaleMir223-/Y or (B) maleMir223-/- mice was
analyzed at 8–12 weeks of age. The absolute number of peripheral blood mononuclear cells (PBMNC),
neutrophils (PMN, Gr-1HiCD115-), monocytes (Mono, Gr-1INTCD115+), B cells (B220+), and T cells (CD3e+)
are shown. All data represent the mean ± SEM. *p<0.05.
doi:10.1371/journal.pone.0119304.g001
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distribution of granulocyte-macrophage progenitors (GMPs) number in the bone marrow was
observed inMir223 deficient mice (Figs. 2F and 2G). Whereas, consistent with a prior study
[6], mostMir223 deficient mice had an elevated number of GMP, in a subset it was normal. No
association between gender, age, or clinical infection and GMP number was observed. Similar
to young mice, no increase in neutrophils in the blood or bone marrow was observed in aged
(greater than 6 month old) mice (Fig. 3). The lack of neutrophilia in our cohort contrasts with
original observations ofMir223 deficient mice on a mixed genetic background. The discrepan-
cy is most likely due to strain differences, but it also is possible that differences in the
Fig 2. Loss ofMir223 is associated with minimal perturbations of basal granulopoiesis. (A) Peripheral
blood frommale and female wild-type andMir223 deficient mice (223KO) was analyzed at 8–12 weeks of
age. (B) Absolute number of neutrophils (PMN, Gr-1HiCD115-), monocytes (Mono, Gr-1INTCD115+), B cells
(B220+), and T cells (CD3e+) in peripheral blood. (C) Bone marrow mononuclear cell count (BMMNC). (D)
Representative plots showing the gating strategy to identify mature neutrophils, granulocyte precursors (Pre,
Gr-1INTCD115-) and monocytes. (E) Bone marrow lineage and granulocyte precursor data. (F)
Representative plots showing the gating strategy to identify megakaryocyte-erythroid progenitors (MEP,
CD34-FcγR-), commonmyeloid progenitors (CMP, CD34+FcγR-) or granulocyte-macrophage progenitors
(GMP, CD34+FcγR+); data are gated on lineage-c-kit+sca-1- cells. (G) Progenitor data.
doi:10.1371/journal.pone.0119304.g002
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microbiome between mouse facilities may contribute. Overall, these data suggest that loss of
miRNA-223 results in a subtle increase in basal granulopoiesis in mice.
To evaluate stress granulopoiesis, neutrophil response to the myelosuppressive agent 5-FU
was assessed (Fig. 4A). As expected, 5-FU induced a transient neutropenia that was followed
by a rebound neutrophilia in wild-type mice. A similar degree of neutropenia was induced by
5-FU inMir223 deficient mice. However,Mir223 deficient mice displayed exaggerated rebound
neutrophil production. Since 5-FU primarily affects dividing cells, we assessed the cell cycle
status of granulocyte progenitors. However, no significant difference in cycling cells was ob-
served (Figs. 4B and 4C). Given the kinetics of the neutrophil recovery (peak 17 days after 5-
FU), it is likely that the expanded pool of GMP is responsible for the exaggerated
neutrophil response.
We next quantified hematopoietic progenitors in the bone marrow by flow cytometry; phe-
notypic HSCs were identified either as CD34- c-kit+ lineage- Sca- (KLS) cells or as
CD150+CD48- KLS cells (Figs. 5A and 5B) [14]. Although there was a modest increase in
CD150+ CD48- KLS cells, no difference in multipotent-progenitors (MPP), CD34- KLS cells or
dormant HSCs (Flt3- CD34- CD150+ CD48- KLS cells) was observed (Fig. 5B). Moreover, the
percentage of CD150+ KSL cells in the G0 phase of the cell cycle was similar to controls (Figs.
5C and 5D), suggesting that miR-223 is not required to maintain HSC quiescence. Competitive
repopulation assays showed thatMir223 deficient HSCs had similar long-term repopulating
activity as control HSCs (Fig. 5E). Likewise, analysis of the contribution ofMir223 deficient
cells to the different lineages revealed no myeloid bias, although a modest reduction to T cells
was observed (Fig. 5F). Finally, serial transplantation assays showed that self-renewal capacity
Fig 3. Neutrophils counts are normal in agedMir223 deficient mice. (A and B) Wild-type andMir223 deficient (223KO) mice at least 6 months old were
analyzed for (A) peripheral blood or (B) bone marrow neutrophil counts. The absolute number of neutrophils (PMN, Gr-1HiCD115-) is shown. All data
represent the mean ± SEM.
doi:10.1371/journal.pone.0119304.g003
MiR-223 HSCMaintenance
PLOS ONE | DOI:10.1371/journal.pone.0119304 March 20, 2015 5 / 9
is normal inMir223 deficient HSCs (Fig. 5G). Thus,Mir223 deficient HSCs have normal long-
term repopulating activity, self-renewal capacity, and quiescence, showing that miR-223 is not
required for HSC maintenance.
Collectively, these data show that miR-223 loss results in a modest expansion of myeloid
progenitors without significant effects on HSCs. This contrasts with the HSC exhaustion that is
Fig 4. Loss ofMir223 is associated with an increased stress granulopoiesis response. (A) Wild-type andMir223 deficient mice (223KO) were treated
with 150 mg/kg of 5-FU and neutrophil counts were followed for 35 days (n = 8–10 mice per cohort from two independent experiments). (B) Representative
plots showing Ki-67 and DAPI staining of GMPs. Harvested on day 14 following 5-FU. (C) Shown is the percentage of GMPs in the G2/M/S phase of the cell
cycle. All data represent the mean ± SEM. *p<0.05, **p<0.005, ***p<0.001.
doi:10.1371/journal.pone.0119304.g004
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observed in mice with a myeloproliferative disorder caused by expression of activating muta-
tions of JAK2 or FLT3 [15,16]. The pathways leading to myeloid expansion associated with acti-
vating mutations of tyrosine kinases genes and miR-223 loss are likely to be distinct. However,
it also is possible that the severity of myeloid expansion determines whether HSCs are affected.
In support of the latter possibility, mice carrying a D835Y FLT3mutation have a less aggressive
myeloproliferative phenotype compared with FLT3-ITD, and HSC loss is only seen in the
FLT3-ITDmice [17]. Our data show that deletion ofMir223 is not sufficient to induce a
Fig 5. Loss ofMir223 is not associated with alterations in HSC number or function. (A) Representative plots showing the gating strategy to identify
multipotent progenitors (MPP, CD34+Flt3+), CD34-KLS (CD34-Flt3-KLS), or CD150+CD48-KLS cells. (B) Progenitor data for 8–12 week old wild-type (WT) or
pooled male and female Mir223 deficient mice (223KO). (C) Representative plots showing cell cycle analysis of CD150+CD48-KLS cells. (D)
CD150+CD48-KLS cell cycle data. (E) Wild-type orMir223 deficient bone marrow (Ly5.2) was mixed at a 1:1 ratio with wild-type (Ly5.1) competitor bone
marrow and transplanted into irradiated recipients (Ly5.1/5.2). Shown is the percentage of Ly5.2 donor cells (n = 9–10 mice from two independent
experiments). (F) Lineage distribution in the bone marrow 24 weeks after transplantation. (G) Serial transplants were performed with either Ly5.2 wild-type or
Mir223 deficient donor marrow. The percentage of donor Ly5.2 cells in the blood 6–8 weeks after transplantation is shown. (n = 4–5 mice per cohort at each
time point). All data represent the mean ± SEM. *p<0.05, **p<0.005, ***p<0.001.
doi:10.1371/journal.pone.0119304.g005
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myeloproliferative disorder in mice, suggesting that loss of this gene is likely not an initiating
event in AML. MiR-223 silencing is often seen in association with specific mutations, such as
AML-ETO. Whether miR-223 loss cooperates with AML-ETO or other oncogenes to induce
AML will require further study.
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